Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.
(2015) In Blood 126(1). p.36-41- Abstract
- Central Nervous System (CNS) relapse in non-Hodgkin lymphomas (NHL) carries a very poor prognosis. Risk factors and outcome have been studied in aggressive B-cell lymphomas but very little is known about the risk in peripheral T-cell lymphoma (PTCL). We aimed at analyzing risk factors for CNS involvement at first relapse or progression, and the outcome of these patients, in a large population-based cohort of PTCL patients. Twenty-eight out of 625 patients (4.5%) developed CNS disease over time. In multivariable analysis disease characteristics at diagnosis independently associated with an increased risk of later CNS involvement were involvement of >1 extranodal site (Hazard Ratio [HR] 2.60, 95% Confidence Interval [95% CI] 1.07-6.29,... (More)
- Central Nervous System (CNS) relapse in non-Hodgkin lymphomas (NHL) carries a very poor prognosis. Risk factors and outcome have been studied in aggressive B-cell lymphomas but very little is known about the risk in peripheral T-cell lymphoma (PTCL). We aimed at analyzing risk factors for CNS involvement at first relapse or progression, and the outcome of these patients, in a large population-based cohort of PTCL patients. Twenty-eight out of 625 patients (4.5%) developed CNS disease over time. In multivariable analysis disease characteristics at diagnosis independently associated with an increased risk of later CNS involvement were involvement of >1 extranodal site (Hazard Ratio [HR] 2.60, 95% Confidence Interval [95% CI] 1.07-6.29, p=0.035), skin (HR 3.51, 95% CI 1.26-9.74, p=0.016) and gastrointestinal involvement (HR 3.06, 95% CI 1.30-7.18, p=0.010). The outcome of relapsed/refractory patients was very poor and CNS involvement was not associated with a significantly worse outcome compared to relapsed/refractory patients without CNS involvement in multivariable analysis (HR 1.6, 95% CI 0.96-2.6, p=0.074). The results from the present study indicate that CNS relapse in PTCL occurs at a frequency similar to what is seen in aggressive B-cell lymphomas, but the poor outcomes in relapse are largely driven by systemic rather than CNS disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5453630
- author
- Ellin, Fredrik LU ; Landström, Jenny ; Jerkeman, Mats LU and Relander, Thomas LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 126
- issue
- 1
- pages
- 36 - 41
- publisher
- American Society of Hematology
- external identifiers
-
- pmid:25957393
- wos:000357696200009
- scopus:84937826373
- pmid:25957393
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2014-12-616961
- language
- English
- LU publication?
- yes
- id
- 6a9d6aac-289f-42ae-9ce2-91c9585bcc4c (old id 5453630)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25957393?dopt=Abstract
- date added to LUP
- 2016-04-01 10:15:43
- date last changed
- 2022-04-04 08:16:27
@article{6a9d6aac-289f-42ae-9ce2-91c9585bcc4c,
abstract = {{Central Nervous System (CNS) relapse in non-Hodgkin lymphomas (NHL) carries a very poor prognosis. Risk factors and outcome have been studied in aggressive B-cell lymphomas but very little is known about the risk in peripheral T-cell lymphoma (PTCL). We aimed at analyzing risk factors for CNS involvement at first relapse or progression, and the outcome of these patients, in a large population-based cohort of PTCL patients. Twenty-eight out of 625 patients (4.5%) developed CNS disease over time. In multivariable analysis disease characteristics at diagnosis independently associated with an increased risk of later CNS involvement were involvement of >1 extranodal site (Hazard Ratio [HR] 2.60, 95% Confidence Interval [95% CI] 1.07-6.29, p=0.035), skin (HR 3.51, 95% CI 1.26-9.74, p=0.016) and gastrointestinal involvement (HR 3.06, 95% CI 1.30-7.18, p=0.010). The outcome of relapsed/refractory patients was very poor and CNS involvement was not associated with a significantly worse outcome compared to relapsed/refractory patients without CNS involvement in multivariable analysis (HR 1.6, 95% CI 0.96-2.6, p=0.074). The results from the present study indicate that CNS relapse in PTCL occurs at a frequency similar to what is seen in aggressive B-cell lymphomas, but the poor outcomes in relapse are largely driven by systemic rather than CNS disease.}},
author = {{Ellin, Fredrik and Landström, Jenny and Jerkeman, Mats and Relander, Thomas}},
issn = {{1528-0020}},
language = {{eng}},
number = {{1}},
pages = {{36--41}},
publisher = {{American Society of Hematology}},
series = {{Blood}},
title = {{Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.}},
url = {{http://dx.doi.org/10.1182/blood-2014-12-616961}},
doi = {{10.1182/blood-2014-12-616961}},
volume = {{126}},
year = {{2015}},
}